Nucleix: Funding, Investors & Team (Sep 2026)
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Nucleix has raised $77.0M across 2 funding rounds on record, the most recent an undisclosed round of $22.0M announced in Jan 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nucleix Company Profile and Key Stats
Latest funding round on record: Jan 2022.
Nucleix Funding Rounds
Nucleix raised $55.0M in an undisclosed round announced in Apr 2021.
9 months later, an undisclosed round of $22.0M was announced in Jan 2022.
Nucleix Founders and Leadership Team
Contact details for the Nucleix team: 1 of 1 has an email address on file.
Start 14-day free trial →Nucleix Funding Compared to Other Biotechnology Startups
Nucleix's latest round of $22.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nucleix in Biotechnology and Rehovot
Companies Similar to Nucleix
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
Nucleix Funding FAQs
What does Nucleix do?
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
How much funding has Nucleix raised?
Nucleix has raised $77.0M across 2 rounds on record. The most recent is an undisclosed round of $22.0M announced in Jan 2022.
When did Nucleix last raise funding?
Nucleix's most recent funding round on record is an undisclosed round of $22.0M, announced in Jan 2022.
Who is the CEO of Nucleix?
Chris Hibberd is listed as CEO at Nucleix.
Where is Nucleix headquartered?
Nucleix is based in Rehovot, Hamerkaz, Israel.
How many employees does Nucleix have?
Nucleix is in the 11-50 employee band.
How does Nucleix's funding compare to other Biotechnology startups?
Nucleix's latest round of $22.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Nucleix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nucleix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.